Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
24
7
2020
Statut:
epublish
Résumé
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
Identifiants
pubmed: 32702732
doi: 10.21203/rs.3.rs-40198/v1
pmc: PMC7373143
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI128913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181045
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA107399
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Vaccine. 2013 Sep 6;31(39):4247-51
pubmed: 23523407
J Gen Virol. 2007 Dec;88(Pt 12):3249-3259
pubmed: 18024893
J Virol. 2013 Feb;87(3):1322-32
pubmed: 23152525
J Virol. 2018 Sep 12;92(19):
pubmed: 30045984
PLoS One. 2018 Jan 19;13(1):e0188453
pubmed: 29351298
J Virol. 2004 Apr;78(8):3965-76
pubmed: 15047812
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):9977-81
pubmed: 1438247
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Blood. 2017 Jan 5;129(1):114-125
pubmed: 27760761
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
EBioMedicine. 2020 May;55:102768
pubmed: 32344202
Vaccine. 2010 Feb 10;28(6):1547-57
pubmed: 19969118
J Virol. 2009 Jul;83(14):7176-84
pubmed: 19420086
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Virology. 1997 Nov 24;238(2):198-211
pubmed: 9400593
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
PLoS Pathog. 2014 Nov 20;10(11):e1004524
pubmed: 25412505
J Mol Biol. 1988 Feb 5;199(3):399-413
pubmed: 3351934
J Virol. 1990 Oct;64(10):5029-35
pubmed: 2398534
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18
pubmed: 28762491
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
J Virol. 1986 Aug;59(2):249-59
pubmed: 3016294
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Exp Med. 2005 Jan 3;201(1):95-104
pubmed: 15623576
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51
pubmed: 1438287
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Virol. 1987 Jun;61(6):1957-63
pubmed: 3033323
Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.17
pubmed: 18265124
J Vis Exp. 2019 Mar 1;(145):
pubmed: 30882796
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
J Virol. 2011 Oct;85(20):10582-97
pubmed: 21775467
Ann Intern Med. 2020 Mar 3;172(5):306-316
pubmed: 32040960
Vaccine. 1996 Oct;14(15):1451-8
pubmed: 8994321
Cell. 1986 Jun 20;45(6):879-84
pubmed: 3085958
Zentralbl Veterinarmed B. 1966 Feb;13(1):1-13
pubmed: 4288045
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
Virology. 1998 May 10;244(2):365-96
pubmed: 9601507
Cold Spring Harb Symp Quant Biol. 1983;47 Pt 2:723-9
pubmed: 6574869
Vaccine. 1988 Dec;6(6):504-8
pubmed: 2854339
Oncoimmunology. 2017 Aug 11;6(12):e1363138
pubmed: 29209571
J Virol Methods. 2018 Jan;251:30-37
pubmed: 28989096
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nucleic Acids Res. 1979 Nov 24;7(6):1513-23
pubmed: 388356
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Vaccine. 2013 Sep 6;31(39):4241-6
pubmed: 23523410